Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol. 2015 Nov; 171(3):373-7.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Bortezomib
Disease-Free Survival
Doxorubicin
Female
Follow-Up Studies
Humans
Male
Middle Aged
Multiple Myeloma
Polyethylene Glycols
Survival Rate
Time Factors

authors with profiles

Richard A. Larson